促红素治疗血透患者肾性贫血的疗效与安全性观察

Clinical observation on the efficacy and safety of EPO in treating renal anemia in patients on maintenance hemodialysis

目的促红细胞生成素(EPO)治疗维持性血液透析(MHD)患者肾性贫血的有效性和安全性。方法选择2005年6月～2009年5月我院维持性血透患者38例,行EPO皮下或静脉注射,于用药前及用药后4周检测Hb、HCT、RBC等指标,同时观察临床症状改善情况,有无不良反应。结果治疗4周后Hb、HCT、RBC比用药前显著升高,差异有统计学意义。结论 EPO治疗MHD患者的肾性贫血安全有效。

Objective To observe the efficacy and safety of EPO in treating renal anemia in maintenance hemodialysis patients.Methods From june 2005 to may 2009,38 maintenance hemodialysis patients selected from hospital patients in our hospital were treated with EPO,IH or IV.The changes of the indice of HB、HCT、RBC of maintenance hemodialysis patients,their clinical improving and the adverse effect was evaluated.Results The levels of HB、HCT and RBC of the patients with maintenance hemodialysis who accepted the treatment with EPO for 4 weeks increased in comparison with normal control before the treatment with EPO,and the difference has significance（P0.05）.None adverse effect was observed.Conclusion EPO is effective and safe in treating renal anemia in maintenance hemodialysis patients.